Although direct synergism between SREBP1 inhibitors and chemotherapy or immunotherapy has not been clinically demonstrated, targeting SREBP1 may enhance the effectiveness of these treatments by altering tumor metabolism and immune responses. The gene discussed is SREBF1; the disease is neoplasm.